Three new treatments for dry eye disease and a new procedure and remote monitoring platform for glaucoma are due to debut in 2024, with more in the pipeline.
The FDA announced that two FDA advisory committees will meet in March to discuss proposed changes to the embattled program to minimize burden on patients, pharmacies, and prescribers."